LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Inicio・Lista de Acciones・Merck & Co Inc.

Merck & Co Inc.

Cerrado

Sector Salud

117.82 -0.52

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

117.67

Máximo

118.19

Métricas clave
By Trading Economics
Ingresos	693M 5.5B
Ventas	310M 16B
P/B Media del Sector	137.56 103.001
BPA	2.28
Margen de beneficio	33.861
Empleados	72,000
EBITDA	491M 7.4B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+18.88 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024
Fecha Próximo Dividendo	7 oct 2024
Próxima Fecha de Ex Dividendo	16 sept 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	1.8B 300B
Apertura anterior	118.34
Cierre anterior	117.82

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

116.6 / 118.395 Soporte y Resistencia

Merck & Co Inc. Gráfico

Noticias Relacionadas

9 ago 2024, 11:14 UTC

Adquisiciones, fusiones, absorciones

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

30 jul 2024, 14:00 UTC

Ganancias

Trending: Merck 2Q Profit Beats Expectations; Fiscal Year Adjusted EPS Outlook Lowered

30 jul 2024, 11:17 UTC

Ganancias

Merck Swings to 2Q Profit Ahead of Views, Lowers FY24 Adjusted EPS Outlook

3 sept 2024, 17:22 UTC

Principales Noticias

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

12 ago 2024, 14:30 UTC

Adquisiciones, fusiones, absorciones

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 ago 2024, 09:30 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1 ago 2024, 15:56 UTC

Ganancias

Merck Created the World's Biggest Drug. Now It -2-

1 ago 2024, 15:56 UTC

Ganancias

Merck Created the World's Biggest Drug. Now It Has to Replace It. -- Barrons.com

30 jul 2024, 15:53 UTC

Ganancias

Nasdaq Dives As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Updates) -- IBD

30 jul 2024, 15:28 UTC

Charlas de Mercado

Ganancias

Merck's Keytruda Continues to See Growth in U.S., Abroad -- Market Talk

30 jul 2024, 13:45 UTC

Ganancias

Trending: Merck 2Q Profit Beats Expectations; FY Adj EPS Outlook Lowered

30 jul 2024, 10:45 UTC

Ganancias

Merck Beats Profit And Sales Expectations Amid Keytruda Strength, But Provides Mixed Full-Year Outlook -- MarketWatch

30 jul 2024, 10:32 UTC

Ganancias

Merck Revised 2024 Adjusted EPS View Includes 51c/Share Charge on EyeBio Deal >MRK

30 jul 2024, 10:31 UTC

Ganancias

Merck 2Q Sales Rose 11% Ex-Forex >MRK

30 jul 2024, 10:31 UTC

Ganancias

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short -- IBD

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Keytruda Sales Up 16% >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Pharmaceutical Sales $14.41B >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Keytruda Sales $7.27B >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Gardasil/Gardasil 9 Sales Up 1% >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Januvia/Janumet Sales Down 27% >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Net $5.46B >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Januvia/Janumet Sales $629M >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Pharmaceutical Sales Up 7% >MRK

30 jul 2024, 10:30 UTC

Ganancias

Merck 2Q Gardasil/Gardasil 9 Sales $2.48B >MRK

30 jul 2024, 08:38 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Microsoft, CrowdStrike, F5, Lattice Semiconductor, BP, Tilray, and More -- Barrons.com

28 jul 2024, 23:02 UTC

Principales Noticias

Stocks Poised for Higher Open -- Barrons.com

12 jul 2024, 10:45 UTC

Adquisiciones, fusiones, absorciones

Merck to Post 3Q Charge of About $1.3 Billion, or 50c/Share, on EyeBio Deal >MRK

12 jul 2024, 10:45 UTC

Adquisiciones, fusiones, absorciones

Merck Completes Acquisition Of EyeBio >MRK

9 jul 2024, 12:30 UTC

Adquisiciones, fusiones, absorciones

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9 jul 2024, 12:29 UTC

Adquisiciones, fusiones, absorciones

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

Comparación entre iguales

Cambio de precio

Merck & Co Inc. Esperado

Precio Objetivo

By TipRanks

18.88% repunte

Estimación a 12 meses

Media 140.09 USD 18.88%

Máximo 155 USD

Mínimo 125 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para Merck & Co Inc. Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

116.6 / 118.395Soporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.